Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
GIANT is an open-label, multi-center, randomized, perioperative (neoadjuvant followed by adjuvant), phase 2 trial with a safety lead-in phase to investigate the feasibility, safety and tolerability, and establish the biological activity of nivolumab with or without relatlimab in patients with isocitrate dehydrogenase (IDH) wildtype newly diagnosed glioblastoma (ndGBM).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraził zgodę na udział w badaniu.
- •Pacjent ma 18 lat lub więcej.
- •Pacjent ma podejrzenie lub potwierdzoną diagnozę glejaka i nie był wcześniej leczony na ten nowotwór mózgu.
- •Pacjent wymaga operacji usunięcia guza.
- •Pacjent zgadza się na planowane zabiegi chirurgiczne.
- •Pacjent zgadza się na pobranie próbek biologicznych do badań.
- •Pacjent ma odpowiednie wyniki badań krwi (liczba neutrofilów, płytek krwi, hemoglobina) oraz krzepnięcia.
- •Pacjent ma prawidłowe wyniki badań czynności nerek i wątroby.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 19, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Memorial Sloan Kettering Cancer Center
New York, United States
Duke University
Durham, United States
Peter MacCallum Cancer Centre
Parkville, Australia
Trial contact
Mustafa Khasraw
Brain Intake office
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.